Skip to main content
. 2020 Jan 21;111(2):528–535. doi: 10.1111/cas.14252

Figure 2.

Figure 2

Predicted mean overall survival (OS) based on 240 mg Q2W or 3 mg/kg Q2W dosing in patients from Japanese studies in patients with the following tumor types: melanoma (A); squamous non–small cell lung cancer (SQ‐NSCLC) (B); non–squamous non–small cell lung cancer (NSQ‐NSCLC) (C). CI, confidence interval; NIVO, nivolumab; Q2W, every 2 wk